利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.016 秒)

    Analogs of gastric inhibitory polypeptide and their use of treatment of diabetes
    1.
    发明申请
    Analogs of gastric inhibitory polypeptide and their use of treatment of diabetes 有权
    胃抑制多肽的类似物及其治疗糖尿病的用途

    公开(公告)号：US20050277590A1

    公开(公告)日：2005-12-15

    申请号：US11090825

    申请日：2005-03-25

    申请人： Finbarr O'Harte ,  Peter Flatt

    发明人： Finbarr O'Harte ,  Peter Flatt

    IPC分类号： A61K38/00 ,  A61K38/22 ,  A61K38/26 ,  A61P5/48 ,  C07K14/575

    CPC分类号： C07K14/575 ,  A61K38/00

    摘要： The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.

    摘要翻译： 本发明提供刺激胰岛素释放的肽。 基于GIP 1-42的肽包括增强和影响分泌和/或具有增强的降解抗性的取代和/或修饰。 本发明还提供N末端修饰GIP的方法和肽类似物用于治疗糖尿病的用途。

    Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
    2.
    发明申请
    Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity 审中-公开
    用于治疗糖尿病，胰岛素抵抗和肥胖的GIP的肽类似物

    公开(公告)号：US20080009603A1

    公开(公告)日：2008-01-10

    申请号：US11825293

    申请日：2007-07-03

    申请人： Victor Gault ,  Finbarr O'Harte ,  Nigel Irwin ,  Peter Flatt

    发明人： Victor Gault ,  Finbarr O'Harte ,  Nigel Irwin ,  Peter Flatt

    IPC分类号： A61K38/22

    CPC分类号： C07K14/575 ,  A61K38/00 ,  Y10T29/4935

    摘要： The present invention provides peptide analogues which are antagonists of gastric inhibitory peptide (GIP). The peptides, based on GIP 1-42 include substitutions and/or modifications which have enhanced resistance to degradation by the enzyme dipeptidyl peptidase IV (DPP IV). The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.

    摘要翻译： 本发明提供作为胃抑制肽（GIP）拮抗剂的肽类似物。 基于GIP 1-42的肽包括通过酶二肽基肽酶IV（DPP IV）具有增强的降解抗性的取代和/或修饰。 本发明还提供N末端修饰GIP的方法和肽类似物用于治疗糖尿病的用途。

    Glycated insulin as a biomarker for diagnosis and monitoring of diabetes
    3.
    发明申请
    Glycated insulin as a biomarker for diagnosis and monitoring of diabetes 审中-公开
    糖化胰岛素作为糖尿病诊断和监测的生物标志物

    公开(公告)号：US20060121532A1

    公开(公告)日：2006-06-08

    申请号：US10528537

    申请日：2003-09-19

    申请人： Aine McKillop ,  Finbarr O'Harte ,  Peter Flatt

    发明人： Aine McKillop ,  Finbarr O'Harte ,  Peter Flatt

    IPC分类号： G01N33/53 ,  C12Q1/54

    CPC分类号： G01N33/6893 ,  G01N33/74 ,  G01N2333/62 ,  G01N2400/02 ,  G01N2800/042

    摘要： One of the major pathophysiological consequences of long term elevation of plasma glucose in diabetes is an increase in the non-enzymatic glycation of proteins. Contrary to expectations the present inventors have determined that individuals with well controlled short duration diabetes have particularly high concentrations of glycated insulin which decrease with increased disease severity and duration of diabetes. Further, a small proportion of apparently normal healthy individuals exhibit high glycated insulin levels in line with expected incidence of diabetes in the population. Methods of predicting the onset of diabetes and for monitoring the progression of diabetes by measuring the concentration of Glycated Insulin and the progression of diabetes are disclosed.

    摘要翻译： 糖尿病血浆葡萄糖长期升高的主要病理生理后果之一是蛋白质的非酶促糖化作用的增加。 与预期相反，本发明人已经确定，具有良好控制的短期糖尿病的个体具有特别高浓度的糖化胰岛素，其随着疾病严重性和糖尿病持续时间的增加而降低。 此外，一小部分明显正常的健康个体表现出高糖化胰岛素水平，符合人群糖尿病预期发病率。 公开了通过测量糖化胰岛素的浓度和糖尿病进展来预测糖尿病发病和监测糖尿病进展的方法。

    Peptide analogues of GIP for treatment of diapetes, insulin resistance and obesity
    4.
    发明申请
    Peptide analogues of GIP for treatment of diapetes, insulin resistance and obesity 有权
    GIP的肽类似物用于治疗diapetes，胰岛素抵抗和肥胖

    公开(公告)号：US20070167370A1

    公开(公告)日：2007-07-19

    申请号：US11713892

    申请日：2007-03-05

    申请人： Victor Gault ,  Finbarr O'Harte ,  Nigel Irwin ,  Peter Flatt

    发明人： Victor Gault ,  Finbarr O'Harte ,  Nigel Irwin ,  Peter Flatt

    IPC分类号： A61K38/22

    CPC分类号： C07K14/575 ,  A61K38/00 ,  Y10T29/4935

    摘要： The present invention provides peptide analogues which are antagonists of gastric inhibitory peptide (GIP). The peptides, based on GIP 1-42 include substitutions and/or modifications which have enhanced resistance to degradation by the enzyme dipeptidyl peptidase IV (DPP IV). The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.

    摘要翻译： 本发明提供作为胃抑制肽（GIP）拮抗剂的肽类似物。 基于GIP 1-42的肽包括通过酶二肽基肽酶IV（DPP IV）具有增强的降解抗性的取代和/或修饰。 本发明还提供N末端修饰GIP的方法和肽类似物用于治疗糖尿病的用途。